Developing BACE-1 inhibitors for FXS

Frontiers in Cellular Neuroscience

Volumn , Issue MAY, 2013, Pages

  Westmark, Cara J ^a   Berry Kravis, Elizabeth M ^b   Ikonomidou, Chrysanthy ^a   Yin, Jerry C P ^c   Puglielli, Luigi ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; BACE 1; Fragile X syndrome; MGlur5

Indexed keywords

ACOMPROSATE; ALPHA TOCOPHEROL; ARBACLOFEN; ASCORBIC ACID; BETA SECRETASE 1; BETA SECRETASE 1 INHIBITOR; DONEPEZIL; ENZYME INHIBITOR; FENOBAM; GANAXOLONE; LITHIUM; MEMANTINE; MEVINOLIN; MINOCYCLINE; OCTAHYDRO 4 HYDROXY 4 [(3 METHYLPHENYL)ETHYNYL] 1H INDOLE 1 CARBOXYLIC ACID METHYL ESTER; R 04917523; SERTRALINE; STX 107; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CATABOLISM; CYTOKINE PRODUCTION; DENDRITE; DRUG EFFICACY; DRUG SAFETY; ENDOCYTOSIS; ENZYME INHIBITION; FRAGILE X SYNDROME; HOMEOSTASIS; LONG TERM DEPRESSION; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SYNAPSE; SYNAPTOGENESIS; TREATMENT RESPONSE; VALIDATION PROCESS;

EID: 84877276306     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2013.00077     Document Type: Article

References (96)

1. Asai, M., Iwata, N., Tomita, T., Iwatsubo, T., Ishiura, S., Saido, T.C., Maruyama, K. (2010). Efficient four-drug cocktail therapy targeting amyloid-beta peptide for Alzheimer's disease. J Neurosci Res. 88, 3588-3597.
2. Auerbach, B.D., Osterweil, E.K., Bear, M.F. (2011). Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature. 480, 63-68.
3. Bassell, G.J., Warren, S.T. (2008). Fragile X syndrome: Loss of local mRNA regulation alters synaptic development and function. Neuron. 60, 201-214.
4. Bear, M.F., Huber, K.M., Warren, S.T. (2004). The mGluR theory of fragile X mental retardation. Trends Neurosci. 27, 370-377.
5. Beckel-Mitchener, A., Greenough, W.T. (2004). Correlates across the structural, functional, and molecular phenotypes of fragile X syndrome. Ment Retard Dev Disabil Res Rev. 10, 53-59.
6. Berry-Kravis, E., Knox, A., Hervey, C. (2011). Targeted treatments for fragile X syndrome. J Neurodev Disord. 3, 193-210.
7. Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D.V., Hagerman, R. (2009.) A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet. 46, 266-271.
8. Berry-Kravis, E., Sumis, A., Hervey, C., Nelson, M., Porges, S.W., Weng, N., Weiler, I.J., Greenough, W.T. (2008). Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 29, 293-302.
9. Berry-Kravis, E.M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., Mu, Y., Nguyen, D.V., Gonzalez-Heydrich, J., Wang, P.P., Carpenter, R.L., Bear, M.F., Hagerman, R.J. (2012). Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Sci Transl Med. 4, 152ra127.
10. Bhakar, A.L., Dolen, G., Bear, M.F. (2012). The pathophysiology of fragile X (and what it teaches us about synapses). Annu Rev Neurosci. 35, 417-443
11. Bushey, D., Tononi, G., Cirelli, C. (2011). Sleep and synaptic homeostasis: Structural evidence in drosophila. Science. 332, 1576-1581.
12. Caccamo, A., Maldonado, M.A., Majumder, S., Medina, D.X., Holbein, W., Magri, A., Oddo, S. (2011). Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40- mediated mechanism. J Biol Chem. 286, 8924-8932.
13. Cao, Q., Huang, Y.S., Kan, M.C., Richter, J.D. (2005). Amyloid precursor proteins anchor CPEB to membranes and promote polyadenylation-induced translation. Mol Cell Biol. 25, 10930-10939.
14. Casley, C.S., Lakics, V., Lee, H.G., Broad, L.M., Day, T.A., Cluett, T., Smith, M.A., O'Neill, M.J., Kingston, A.E. (2009). Up-regulation of astrocyte metabotropic glutamate receptor 5 by amyloid-beta peptide. Brain Res. 1260, 65-75.
15. Chang, W.P., Huang, X., Downs, D., Cirrito, J.R., Koelsch, G., Holtzman, D.M., Ghosh, A.K., Tang, J. (2011). Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. Faseb J. 25, 775-784.
16. Chasseigneaux, S., Dinc, L., Rose, C., Chabret, C., Coulpier, F., Topilko, P., Mauger, G., Allinquant, B. (2011). Secreted amyloid precursor protein beta and secreted amyloid precursor protein alpha induce axon outgrowth in vitro through Egr1 signaling pathway. PLoS One. 6, e16301.
17. Chen, S., Wang, J.M., Irwin, R.W., Yao, J., Liu, L., Brinton, R.D. (2011). Allopregnanolone promotes regeneration and reduces beta-amyloid burden in a preclinical model of Alzheimer's disease. PLoS One. 6, e24293.
18. Claasen, A.M., Guevremont, D., Mason-Parker, S.E., Bourne, K., Tate, W.P., Abraham, W.C., Williams, J.M. (2009). Secreted amyloid precursor protein-alpha upregulates synaptic protein synthesis by a protein kinase G- dependent mechanism. Neurosci Lett. 460, 92-96.
19. Cochet, M., Donneger, R., Cassier, E., Gaven, F., Lichtenthaler, S.F., Marin, P., Bockaert, J., Dumuis, A., Claeysen, S. (2013). 5-HT(4) receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10. ACS Chem Neurosci. 4, 130-140.
20. Costantini, C., Ko, M.H., Jonas, M.C., Puglielli, L. (2007). A reversible form of lysine acetylation in the ER and Golgi lumen controls the molecular stabilization of BACE1. Biochem J. 407, 383-395.
21. Cruz-Martin, A., Crespo, M., Portera-Cailliau, C. (2010). Delayed stabilization of dendritic spines in fragile X mice. J Neurosci. 30, 7793-7803.
22. Danysz, W., Parsons, C.G. (2012). Alzheimer's disease, beta-amyloid, glutamate, NMDA receptors and memantine-searching for the connections. Br J Pharmacol. 167, 324-352.
23. de Vrij, F.M., Levenga, J., van der Linde, H.C., Koekkoek, S.K., De Zeeuw, C.I., Nelson, D.L., Oostra, B.A., Willemsen, R. (2008). Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis. 31, 127-132.
24. Ding, Y., Ko, M.H., Pehar, M., Kotch, F., Peters, N.R., Luo, Y., Salamat, S.M., Puglielli, L. (2012).Biochemical inhibition of the acetyltransferases ATase1 and ATase2 reduces beta-secretase (BACE1) levels and abeta generation. J Biol Chem. 287, 8424-8433.
25. Dolen, G., Osterweil, E., Rao, B.S., Smith, G.B., Auerbach, B.D., Chattarji, S., Bear, M.F. (2007). Correction of fragile X syndrome in mice. Neuron. 56, 955-962.
26. Erickson, C.A., Mullett, J.E., McDougle, C.J. (2009). Open-label memantine in fragile X syndrome. J Autism Dev Disord. 39, 1629-1635.
27. Erickson, C.A., Mullett, J.E., McDougle, C.J. (2010). Brief report: Acamprosate in fragile X syndrome. J Autism Dev Disord. 40, 1412-1416.
28. Ferreira, S.T., Klein, W.L. (2011). The abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem. 96, 529-543.
29. Ferretti, M.T., Allard, S., Partridge, V., Ducatenzeiler, A., Cuello, A.C. (2012). Minocycline corrects early, pre¬plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology. J Neuroinflammation. 9, 62-2094-9-62.
30. Ghosh, A.K., Brindisi, M., Tang, J. (2012). Developing beta-secretase inhibitors for treatment of Alzheimer's disease. J Neurochem. 120 Suppl 1, 71-83.
31. Ghosh, A.K., Kumaragurubaran, N., Hong, L., Kulkarni, S., Xu, X., Miller, H.B., Reddy, D.S., Weerasena, V., Turner, R., Chang, W., Koelsch, G., Tang, J. (2008). Potent memapsin 2 (beta-secretase) inhibitors: Design, synthesis, protein-ligand X-ray structure, and in vivo evaluation. Bioorg Med Chem Lett. 18, 1031-1036.
32. Goebel-Goody, S.M., Wilson-Wallis, E.D., Royston, S., Tagliatela, S.M., Naegele, J.R., Lombroso, P.J. (2012). Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model. Genes Brain Behav. 2, e137.
33. Gralle, M., Botelho, M.G., Wouters, F.S. (2009). Neuroprotective secreted amyloid precursor protein acts by disrupting amyloid precursor protein dimers. J Biol Chem. 284, 15016-15025.
34. Gravitz, L. (2011). Drugs: A tangled web of targets. Nature. 475, S9-11.
35. Gross, C., Berry-Kravis, E.M., Bassell, G.J. (2012). Therapeutic strategies in fragile X syndrome: Dysregulated mGluR signaling and beyond. Neuropsychopharmacology. 37, 178-195.
36. Hagerman, R.J., Berry-Kravis, E., Kaufmann, W.E., Ono, M.Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., Picker, J., Gane, L., Tranfaglia, M. (2009). Advances in the treatment of fragile X syndrome. Pediatrics. 123, 378-390.
37. Heo, J.H., Lee, H., Lee, K.M. (2013). The possible role of antioxidant vitamin C in Alzheimer's disease treatment and prevention. Am J Alzheimers Dis Other Demen. 28, 120-125.
38. Heulens, I., D'Hulst, C., Van Dam, D., De Deyn, P.P., Kooy, R.F. (2012). Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav Brain Res. 229, 244-249.
39. Hoe, H.S., Lee, H.K., Pak, D.T. (2012). The upside of APP at synapses. CNS Neurosci Ther. 18, 47-56.
40. Hsieh, H., Boehm, J., Sato, C., Iwatsubo, T., Tomita, T., Sisodia, S., Malinow, R. (2006). AMPAR removal underlies abeta-induced synaptic depression and dendritic spine loss. Neuron. 52, 831-843.
41. Hu, X., Zhou, X., He, W., Yang, J., Xiong, W., Wong, P., Wilson, C.G., Yan, R. (2010). BACE1 deficiency causes altered neuronal activity and neurodegeneration. J Neurosci. 30, 8819-8829.
42. Huber, K.M., Gallagher, S.M., Warren, S.T., Bear, M.F. (2002). Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A. 99, 7746-7750.
43. Indah Winarni, T., Chonchaiya, W., Adams, E., Au, J., Mu, Y., Rivera, S.M., Nguyen, D.V., Hagerman, R.J. (2012). Sertraline may improve language developmental trajectory in young children with fragile x syndrome: A retrospective chart review. Autism Res Treat. 2012, 104-317.
44. Ishida, A., Furukawa, K., Keller, J.N., Mattson, M.P. (1997). Secreted form of beta-amyloid precursor protein shifts the frequency dependency for induction of LTD, and enhances LTP in hippocampal slices. Neuroreport. 8, 2133-2137.
45. Jonas, M.C., Costantini, C., Puglielli, L. (2008). PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. EMBO Rep. 9, 916-922.
46. Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., Malinow, R. (2003). APP processing and synaptic function. Neuron. 37, 925-937.
47. Kang, J.E., Lim, M.M., Bateman, R.J., Lee, J.J., Smyth, L.P., Cirrito, J.R., Fujiki, N., Nishino, S., Holtzman, D.M. (2009). Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 326, 1005-1007.
48. Kelleher, R.J. 3rd, Bear, M.F. (2008). The autistic neuron: Troubled translation? Cell. 135, 401-406.
49. Kelley, D.J., Davidson, R.J., Elliott, J.L., Lahvis, G.P., Yin, J.C., Bhattacharyya, A. (2007). The cyclic AMP cascade is altered in the fragile X nervous system. PLoS One. 2, e931.
50. Ko, M.H., Puglielli, L. (2009). Two endoplasmic reticulum (ER)/ER Golgi intermediate compartment-based lysine acetyltransferases post-translationally regulate BACE1 levels. J Biol Chem. 284, 2482-2492.
51. Koffie, R.M., Hyman, B.T., Spires-Jones, T.L. (2011). Alzheimer's disease: Synapses gone cold. Mol Neurodegener. 6, 63-1326-6-63.
52. Kojro, E., Gimpl, G., Lammich, S., Marz, W., Fahrenholz, F. (2001). Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci U S A. 98, 5815-5820.
53. Lacor, P.N., Buniel, M.C., Chang, L., Fernandez, S.J., Gong, Y., Viola, K.L., Lambert, M.P., Velasco, P.T., Bigio, E.H., Finch, C.E., Krafft, G.A., Klein, W.L. (2004). Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci. 24, 10191-10200.
54. Lee, E.K., Kim, H.H., Kuwano, Y., Abdelmohsen, K., Srikantan, S., Subaran, S.S., Gleichmann, M., Mughal, M.R., Martindale, J.L., Yang, X., Worley, P.F., Mattson, M.P., Gorospe, M. (2010). hnRNP C promotes APP translation by competing with FMRP for APP mRNA recruitment to P bodies. Nat Struct Mol Biol. 17, 732-739.
55. Levenga, J., Hayashi, S., de Vrij, F.M., Koekkoek, S.K., van der Linde, H.C., Nieuwenhuizen, I., Song, C., Buijsen, R.A., Pop, A.S., Gomezmancilla, B., Nelson, D.L., Willemsen, R., Gasparini, F., Oostra, B.A. (2011). AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol Dis. 42, 311-317.
56. Liao, L., Park, S.K., Xu, T., Vanderklish, P., Yates, J.R. 3rd (2008). Quantitative proteomic analysis of primary neurons reveals diverse changes in synaptic protein content in fmr1 knockout mice. Proc Natl Acad Sci U S A. 105, 15281-15286.
57. Luscher, C., Huber, K.M. (2010). Group 1 mGluR-dependent synaptic long-term depression: Mechanisms and implications for circuitry and disease. Neuron. 65, 445-459.
58. Ma, T., Klann, E. (2012). Amyloid beta: Linking synaptic plasticity failure to memory disruption in Alzheimer's disease. J Neurochem. 120 Suppl 1, 140-148.
59. Ma, T., Hoeffer, C.A., Capetillo-Zarate, E., Yu, F., Wong, H., Lin, M.T., Tampellini, D., Klann, E., Blitzer, R.D., Gouras, G.K. (2010). Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS One. 5, e12845.
60. Malter, J.S., Ray, B.C., Westmark, P.R., Westmark, C.J. (2010). Fragile X syndrome and Alzheimer's disease: Another story about APP and beta-amyloid. Curr Alzheimer Res. 7, 200-206.
61. McBride, S.M., Bell, A.J., Jongens, T.A. (2012). Behavior in a drosophila model of fragile X. Results Probl Cell Differ. 54, 83-117.
62. McBride, S.M., Choi, C.H., Wang, Y., Liebelt, D., Braunstein, E., Ferreiro, D., Sehgal, A., Siwicki, K.K., Dockendorff, T.C., Nguyen, H.T., McDonald, T.V., Jongens, T.A. (2005). Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a drosophila model of fragile X syndrome. Neuron. 45, 753-764.
63. Michalon, A., Sidorov, M., Ballard, T.M., Ozmen, L., Spooren, W., Wettstein, J.G., Jaeschke, G., Bear, M.F., Lindemann, L. (2012). Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron. 74, 49-56.
64. Mines, M.A., Jope, R.S. (2011). Glycogen synthase kinase-3: A promising therapeutic target for fragile x syndrome. Front Mol Neurosci. 4, 35.
65. Morgan, D. (2011). Immunotherapy for Alzheimer's disease. J Intern Med. 269, 54-63.
66. Nalbantoglu, J., Tirado-Santiago, G., Lahsaini, A., Poirier, J., Goncalves, O., Verge, G., Momoli, F., Welner, S.A., Massicotte, G., Julien, J.P., Shapiro, M.L. (1997). Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature. 387, 500-505.
67. Noh, M.Y., Koh, S.H., Kim, Y., Kim, H.Y., Cho, G.W., Kim, S.H. (2009). Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-beta-induced neuronal cell death. J Neurochem. 108, 1116-1125.
68. Osterweil, E.K., Chuang, S.C., Chubykin, A.A., Sidorov, M., Bianchi, R., Wong, R.K., Bear, M.F. (2013). Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron. 77, 243-250.
69. Palop, J.J., Chin, J., Roberson, E.D., Wang, J., Thwin, M.T., Bien-Ly, N., Yoo, J., Ho, K.O., Yu, G.Q., Kreitzer, A., Finkbeiner, S., Noebels, J.L., Mucke, L. (2007). Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 55, 697-711.
70. Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I.M., Ethell, D.W. (2010). Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 10, 91.
71. Parodi, J., Sepulveda, F.J., Roa, J., Opazo, C., Inestrosa, N.C., Aguayo, L.G. (2010). Beta-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure. J Biol Chem. 285, 2506-2514.
72. Pehar, M., Puglielli, L. (2013). Lysine acetylation in the lumen of the ER: A novel and essential function under the control of the UPR. Biochim Biophys Acta. 1833, 686-697.
73. Ray, B., Banerjee, P.K., Greig, N.H., Lahiri, D.K. (2010). Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (Ap) peptide in the human neuroblastoma cells. Neurosci Lett. 470, 1-5.
74. Renner, M., Lacor, P.N., Velasco, P.T., Xu, J., Contractor, A., Klein, W.L., Triller, A. (2010). Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron. 66, 739-754.
75. Roselli, F., Hutzler, P., Wegerich, Y., Livrea, P., Almeida, O.F. (2009). Disassembly of shank and homer synaptic clusters is driven by soluble beta-amyloid(1-40) through divergent NMDAR-dependent signalling pathways. PLoS One. 4, e6011.
76. Ryan, K.A., Pimplikar, S.W. (2005). Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain. J Cell Biol. 171, 327-335.
77. Sahu, J.K., Gulati, S., Sapra, S., Arya, R., Chauhan, S., Chowdhury, M.R., Gupta, N., Kabra, M., Gupta, Y.K., Dwivedi, S.N., Kalra, V. (2012). Effectiveness and safety of donepezil in boys with fragile X syndrome: A double-blind, randomized, controlled pilot study. J Child Neurol. In press.
78. Siopi, E., Cho, A.H., Homsi, S., Croci, N., Plotkine, M., Marchand-Leroux, C., Jafarian-Tehrani, M. (2011). Minocycline restores sAPPalpha levels and reduces the late histopathological consequences of traumatic brain injury in mice. J Neurotrauma. 28, 2135-2143.
79. Sun, X., Meng, X., Zhang, J., Li, Y., Wang, L., Qin, X., Sui, N., Zhang, Y. (2012). GABA attenuates amyloid toxicity by downregulating its endocytosis and improves cognitive impairment. J Alzheimers Dis. 31, 635-649.
80. Takashima, A., Noguchi, K., Michel, G., Mercken, M., Hoshi, M., Ishiguro, K., Imahori, K. (1996). Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neurosci Lett. 203, 33-36.
81. Taylor, C.J., Ireland, D.R., Ballagh, I., Bourne, K., Marechal, N.M., Turner, P.R., Bilkey, D.K., Tate, W.P., Abraham, W.C. (2008). Endogenous secreted amyloid precursor protein-alpha regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. Neurobiol Dis. 31, 250-260.
82. Tessier, C.R., Broadie, K. (2012). Molecular and genetic analysis of the drosophila model of fragile X syndrome. Results Probl Cell Differ. 54, 119-156.
83. Tucker, B., Richards, R.I., Lardelli, M. (2006). Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome. Hum Mol Genet. 15, 3446-3458.
84. Vincent, B., Govitrapong, P. (2011). Activation of the alpha-secretase processing of AbetaPP as a therapeutic approach in Alzheimer's disease. J Alzheimers Dis. 24 Suppl 2, 75-94.
85. Wang, L.W., Berry-Kravis, E., Hagerman, R.J. (2010). Fragile X: Leading the way for targeted treatments in autism. Neurotherapeutics. 7, 264-274.
86. Westmark, C.J., Hervey, C.M., Berry-Kravis, E.M., Malter, J.S. (2011). Effect of anticoagulants on amyloid beta-protein precursor and amyloid beta levels in plasma. Alzheimer's Disease and Parkinsonism. 1, 1-3.
87. Westmark, C.J., Westmark, P.R., Malter, J.S. (2013). Soy-based diet exacerbates seizures in mouse models of neurological disease. J Alzheimers Dis. 33, 797-805.
88. Westmark, C.J. (2013). What's hAPPening at synapses? The role of amyloid beta-protein precursor and beta- amyloid in neurological disorders. Mol Psychiatry. 18, 425-434.
89. Westmark, C.J., Westmark, P.R., O'Riordan, K.J., Ray, B.C., Hervey, C.M., Salamat, M.S., Abozeid, S.H., Stein, K.M., Stodola, L.A., Tranfaglia, M., Burger, C., Berry-Kravis, E.M., Malter, J.S. (2011). Reversal of fragile X phenotypes by manipulation of AbetaPP/Abeta levels in Fmr1 mice. PLoS One. 6, e26549.
90. Westmark, C.J., Westmark, P.R., Malter, J.S. (2010). Alzheimer's disease and Down syndrome rodent models exhibit audiogenic seizures. J Alzheimers Dis. 20, 1009-1013.
91. Westmark, C.J., Malter, J.S. (2007). FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol. 5, e52.
92. Wolfe, M.S. (2012). Gamma-secretase as a target for Alzheimer's disease. Adv Pharmacol. 64, 127-153.
93. Yan, Q.J., Rammal, M., Tranfaglia, M., Bauchwitz, R.P. (2005). Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology. 49, 1053-1066.
94. Young, K.F., Pasternak, S.H., Rylett, R.J. (2009). Oligomeric aggregates of amyloid beta peptide 1-42 activate ERK/MAPK in SH-SY5Y cells via the alpha7 nicotinic receptor. Neurochem Int. 55, 796-801.
95. Yu, F., Zhang, Y., Chuang, D.M. (2012). Lithium reduces BACE1 overexpression, beta amyloid accumulation, and spatial learning deficits in mice with traumatic brain injury. J Neurotrauma. 29, 2342-2351.
96. Zheng, H., Koo, E.H. (2011). Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener. 6, 27.